CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idera Pharmaceuticals, Inc. announced today that Timothy Sullivan, Ph.D., Vice President of Development Programs, is scheduled to present an overview of the Company, its product pipeline, and its technology to investors at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, taking place at The New York Palace Hotel in New York City. The presentation is scheduled for Monday, November 7, 2005 at 1:00 p.m. ET in the Kennedy I room.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of targeted immune therapies based on modulation of Toll-like Receptors (TLRs). Idera has identified novel chemical entities that modulate immune responses through interactions with TLR9. The Company continues to identify new drug candidates specific to various diseases, including cancer, infectious diseases and asthma/allergies, based on the differentiated biological activities of its proprietary compounds. The Company’s website is located at http://www.iderapharma.com.
Idera Pharmaceuticals is based in Cambridge, Massachusetts. Idera’s lead candidate is IMO-2055, a TLR9 agonist currently in Phase 2 clinical testing for cancer. Idera is also collaborating with Novartis for the discovery, development, and commercialization of IMO drug candidates targeting asthma and allergies.
Forward-Looking Statements
This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “should,” “could,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera’s technology will advance through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if such products receive approval, they will be successfully distributed and marketed; whether Idera’s cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption “Risk Factors” in Idera’s Quarterly Report on Form 10-Q filed on August 9, 2005, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.
Contacts: Idera Pharmaceuticals, Inc. MacDougall Biomedical Communications 617-679-5500 x5517 508-647-0209 x12 Robert G. Andersen Douglas MacDougall E-mail: randersen@iderapharma.com E-mail: doug@macbiocom.com
Idera Pharmaceuticals, Inc.
CONTACT: Robert G. Andersen of Idera Pharmaceuticals, Inc., +1-617-679-5500 ext. 5517, randersen@iderapharma.com; or Douglas MacDougall ofMacDougall Biomedical Communications, +1-508-647-0209 ext. 12,doug@macbiocom.com
Web site: http://www.iderapharma.com//
